CTLA-4 and ovarian cancer residual tumors: the dark side of debulking surgery.

Even the most effective targeted medicines or debulking surgery may not always result in a full tumor response, leaving patients with residual disease and tumor growth that restricts patient survival. By utilizing MEXPRESS, we investigated the influence of residual HGSOC tumors on patients' overall survival and CTLA-4 expression in residual HGSOC tumors. Keywords: Ovarian cancer; High-grade serous; Debulking surgery; CTLA-4; Residual tumors EN Ovarian cancer High-grade serous Debulking surgery CTLA-4 Residual tumors 2281 2283 3 10/26/23 20231101 NES 231101 To the Editor, Ovarian Cancer (OC) is a global concern, and according to Globocan 2020 projections, the number of women diagnosed with OC worldwide would increase by over 42% by 2040. [Extracted from the article]